docetaxel + liposomal doxorubicin + enoxaparin

A three-drug oncology regimen combining the taxane chemotherapy docetaxel, the anthracycline formulation pegylated liposomal doxorubicin (PLD), and the low-molecular-weight heparin anticoagulant enoxaparin. Docetaxel stabilizes microtubules and inhibits their depolymerization, leading to mitotic arrest and apoptosis in proliferating tumor cells.[9][8] Pegylated liposomal doxorubicin is a liposome-encapsulated, PEGylated form of doxorubicin that intercalates DNA and inhibits topoisomerase II, blocking nucleic acid synthesis; the liposomal PEGylation alters pharmacokinetics and reduces cardiotoxicity compared with conventional doxorubicin.[9][4] Enoxaparin is an anticoagulant used to prevent and treat thromboembolism via antithrombin-mediated inhibition of factor Xa; in cancer regimens it is co-administered for thromboprophylaxis.[9] Clinical exploration of docetaxel plus PLD has occurred in breast cancer settings, including metastatic and neoadjuvant contexts, with mixed tolerability results; adding enoxaparin has been studied in a clinical trial assessing safety and response.[1][3][9][6]

Other names

docetaxel + pegylated liposomal doxorubicin + enoxaparin